<DOC>
	<DOCNO>NCT02396758</DOCNO>
	<brief_summary>The objective study determine optimum dose thrombolytic duration ultrasound procedure treatment acute submassive pulmonary embolism .</brief_summary>
	<brief_title>Optimum Duration Acoustic Pulse Thrombolysis Procedure Acute Pulmonary Embolism</brief_title>
	<detailed_description>Subjects pulmonary embolism RV/LV &gt; 0.9 hemodynamically stable meet eligibility criterion sign inform consent randomize one 4 treatment group ( see ) . 48 hour start treatment , repeat CTA obtain RV/LV obtain . Thereafter , subject follow 12 month echocardiogram obtain clinic visit . Subjects monitor occurrence repeat PE serious adverse event .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Embolism Thrombosis</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<criteria>1 . Male female ≥ 18 year age ≤ 75 year age 2 . CTA evidence proximal PE ( fill defect least one main lobar pulmonary artery ) 3 . PE symptom duration ≤14 day 4 . Submassive PE : RV/LV diameter ≥ 0.9 CTA hemodynamically stable 5 . Must treat within 48 hour diagnosis PE CTA 6 . Signed Informed consent obtain subject Legally Authorized Representative 1 . Stroke transient ischemic attack ( TIA ) , head trauma , active intracranial intraspinal disease within one year 2 . Recent ( within one month ) active bleed major organ 3 . Major surgery within seven day screen study enrollment 4 . Clinician deems subject highrisk catastrophic bleed 5 . History heparininduced thrombocytopenia ( HIT ) 6 . Catheterbased pharmacomechanical treatment PE within 3 day study enrollment 7 . Systolic blood pressure ( SBP ) less 90 mm Hg and/or use vasopressor 8 . Cardiac arrest ( include pulseless electrical activity asystole ) require active cardiopulmonary resuscitation ( CPR ) 9 . Evidence irreversible neurological compromise 10 . Life expectancy &lt; one year 11 . Use thrombolytic glycoprotein IIb/IIIa antagonist within 3 day prior inclusion study 12 . OutofRange Laboratory Values : Hematocrit &lt; 30 % , Platelets &lt; 100 thousand/μL , INR &gt; 3 , 13 . Creatinine outside normal range treat institution 14 . Subject pregnant ( positive pregnancy test ; woman childbearing capacity must test ) breast feed 15 . Active cancer ( metastatic , progressive , treat within last 6 month ) . Exception : subject nonmelanoma primary skin cancer eligible participate study 16 . Known allergy , hypersensitivity , thrombocytopenia heparin , rtPA , iodinate contrast except mildmoderate contrast allergy steroid premedication use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>